Insider Holder Move: Timothy Coughlin Insider Buying for 56,390 Shares of Fate Therapeutics Inc (NASDAQ:FATE)

November 28, 2016 - By Ruchi Gupta

Insider Holder Move: Timothy Coughlin Insider Buying for 56,390 Shares of Fate Therapeutics Inc (NASDAQ:FATE)

Timothy Coughlin Insider Buy

After the publishing of a report filled with Washington-based SEC; a new insider trading deal became apparent. The director of Fate Therapeutics Inc, Timothy Coughlin; performed a purchase in the open market by accumulating 56,390 shares at the avg. market share price which was $2.7 of the firm having a market value near $149,997 U.S Dollars. The probability of this deal remaining unnoticed is little because it’s new, with the director now having in hand 56,390 shares —- that is 0.17% of the Company’s market cap.

Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage

Out of 6 analysts covering Fate Therapeutics (NASDAQ:FATE), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $8 is the highest target while $4 is the lowest. The $6.75 average target is 116.35% above today’s ($3.12) stock price. Fate Therapeutics has been the topic of 6 analyst reports since October 6, 2015 according to StockzIntelligence Inc. On Tuesday, November 8 the stock rating was maintained by Wedbush with “Outperform”. The firm has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. TH Capital initiated Fate Therapeutics Inc (NASDAQ:FATE) rating on Thursday, September 22. TH Capital has “Buy” rating and $8 price target. Wells Fargo initiated Fate Therapeutics Inc (NASDAQ:FATE) on Friday, December 4 with “Outperform” rating. As per Thursday, September 22, the company rating was initiated by Roth Capital. As per Tuesday, October 6, the company rating was initiated by Raymond James.

Insitutional Activity: The institutional sentiment increased to 0.82 in 2016 Q2. Its up 0.26, from 0.56 in 2016Q1. The ratio increased, as 7 funds sold all Fate Therapeutics Inc shares owned while 11 reduced positions. 1 funds bought stakes while 9 increased positions. They now own 13.89 million shares or 11.32% less from 15.66 million shares in 2016Q1.

Goldman Sachs holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 35,966 shares. Jacobs Levy Equity Mngmt Incorporated has 178,647 shares for 0.01% of their US portfolio. Bridgeway Cap Mgmt has invested 0.01% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Redmile Group Lc has invested 0.24% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE). Moreover, Fmr Ltd Liability Corporation has 0% invested in Fate Therapeutics Inc (NASDAQ:FATE) for 4.31 million shares. Tfs Capital Limited Liability reported 20,925 shares or 0.01% of all its holdings. Wells Fargo And Mn, a California-based fund reported 1,000 shares. Manufacturers Life Ins The last reported 184 shares in the company. The New York-based Bancorporation Of Ny Mellon Corp has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). The Texas-based Belmont Advisors Inc has invested 0.65% in Fate Therapeutics Inc (NASDAQ:FATE). Northern Trust Corp accumulated 0% or 25,531 shares. Board Of Trustees Of The Leland Stanford Junior University owns 291,067 shares or 0.07% of their US portfolio. Moreover, Da Davidson And has 0% invested in Fate Therapeutics Inc (NASDAQ:FATE) for 720 shares. Lombard Odier Asset Mngmt (Usa) reported 256,426 shares or 0.05% of all its holdings. Nationwide Fund last reported 22,578 shares in the company.

About 212,177 shares traded hands or 11.91% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 60.61% since April 25, 2016 and is uptrending. It has outperformed by 54.59% the S&P500.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $102.98 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

According to Zacks Investment Research, “Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.”

Analysts await Fate Therapeutics Inc (NASDAQ:FATE) to report earnings on March, 2. They expect $-0.29 earnings per share, down 11.54% or $0.03 from last year’s $-0.26 per share. After $-0.27 actual earnings per share reported by Fate Therapeutics Inc for the previous quarter, Wall Street now forecasts 7.41% negative EPS growth.

Another recent and important Fate Therapeutics Inc (NASDAQ:FATE) news was published by Medgadget.com which published an article titled: “Fate Therapeutics, Inc Clinical Trial Reviews and Clinical Trail Assessment ..” on September 14, 2016.

FATE Company Profile

Fate Therapeutics, Inc. (Fate Therapeutics), incorporated on April 27, 2007, is a clinical-stage biopharmaceutical company. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. The Firm programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. The Company’s adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>